Research Reports | Market Assessment
May 2014

Biomarker-Driven Prescribing in Oncology | Pharmacor | G7 | 2014

Owing to the heterogeneity of cancer, oncology markets are increasingly focusing on personalized therapy approaches that are expected to provide greater efficacy gains. Driving this trend are biomarkers that effectively identify the niche patient populations most likely to respond and derive benefit from targeted therapies. Biomarkers are already entrenched in oncology indications such as breast, colorectal, gastric, and non-small-cell lung cancers and malignant melanoma, where biomarker-driven prescribing has proven highly lucrative.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports